The kallikrein-Kinin system modulates the progression of colorectal liver metastases in a mouse model
Open Access
- 4 April 2018
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-9
Abstract
The Kallikrein-Kinin System (KKS) has been found to play a role in tumor progression in several cancers. The KKS metabolic cascade depends on signalling through two cross talking receptors; bradykinin receptor 1 (B1R) and bradykinin receptor 2 (B2R). Activation of the Kinin receptor is responsible for multiple pathophysiologic functions including increase of vascular permeability and induction of host inflammatory responses that exert diverse effects on tumor growth. B1R and B2R expression on mouse and human CRC cell lines was investigated. Changes in tumor growth and progression was assessed in male CBA mice bearing colorectal liver metastases (CRLM) following treatment with B1R or B2R blockers. In vitro cultures of human SW-480 and mouse colorectal cancer (MoCR) cell lines were examined for changes in their proliferation and migration properties following treatment with B1R or B2R blockers. Both colorectal cancer cell lines tested strongly positive for B1R and B2R expression. Inhibition of both receptors retarded tumor growth but only B1R blockade significantly reduced tumor load and increased tumor apoptosis. Blockade of either receptor reduced tumor vascularization in vivo and significantly inhibited proliferation and migration of colorectal cancer cells in vitro. Taken together, the present study demonstrated that kinin receptor blockade inhibited tumor growth and reduced its invading properties suggesting that KKS manipulation could be a novel target in colorectal cancer therapy.Keywords
Funding Information
- Cure Cancer Australia Foundation
This publication has 46 references indexed in Scilit:
- Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumorCancer Medicine, 2013
- Different cross-talk sites between the renin–angiotensin and the kallikrein–kinin systemsJournal of the Renin-Angiotensin-Aldosterone System, 2013
- Kinin receptors as targets for cancer therapyExpert Opinion on Therapeutic Targets, 2012
- Activation of kinin B1 receptor increases the release of metalloproteases-2 and -9 from both estrogen-sensitive and -insensitive breast cancer cellsCancer Letters, 2010
- Bradykinin‐induced cell migration and COX‐2 production mediated by the bradykinin B1 receptor in glioma cellsJournal of Cellular Biochemistry, 2010
- SELECTIVE TARGETING OF THE TUMOUR VASCULATURE*Anz Journal of Surgery, 2008
- Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinomaJournal of Clinical Pathology, 2005
- A Potential Role of Bradykinin in Angiogenesis and Growth of S-180 Mouse TumorsThe Japanese Journal of Pharmacology, 2001
- A Novel Mitogenic Signaling Pathway of Bradykinin in the Human Colon Carcinoma Cell Line SW-480 Involves Sequential Activation of a Gq/11 Protein, Phosphatidylinositol 3-Kinase β, and Protein Kinase CεJournal of Biological Chemistry, 1998
- Characterization of an animal model of hepatic metastasisJournal of Gastroenterology and Hepatology, 1996